Federal Register / Vol. 66, No. 80 / Wednesday, April 25, 2001 / Notices 20821

Request for Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Whether the

proposed collection of information will

have practical utility; (2) the accuracy of

the agency’s estimate of burden of the

proposed collection of information,

including the validity of the

methodology and assumptions used; (3)

ways to enhance the quality, utility, and

clarity of the information to be

collected; and (4) ways to minimize the

burden of collection of information on

those who are to respond, including the

use of appropriate automated,

electronic, mechanical, or other

technological collection techniques or

other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To

request more information on the

proposed project or to obtain a copy of

data collection plans and instruments,

contact Dr. Diane Bild, Epidemiology

and Biometry Program, Division of

Epidemiology and Clinical

Applications, NHLBI, NIH, II Rockledge

Centre, 6701 Rockledge Drive, MSC

#7934, Bethesda, MD 20892–7934, or

call non-toll-free number (301) 435–

0457, or e-mail your request, including

your address to: bd3@nih.gov.

Comments Due Date

Comments regarding this information

collection are best assured of having

their full effect if received on or before

June 25, 2001.

Dated: April 13, 2001.

Peter J. Savage,

Acting Director, Division of Epidemiology and

Clinical Applications, National Heart, Lung,

and Blood Institute.

[FR Doc. 01–10205 Filed 4–24–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, Molecular

Target Drug Discovery for Cancer.

Date: April 18, 2001.

Time: 12:30 p.m. to 1:30 p.m.

Agenda: To review and evaluate grant

applications.

Place: National Cancer Institute, 6116

Executive Boulevard, Conference Room 8052,

Rockville, MD 20852 (Telephone Conference

Call).

Contact Person: Joyce C. Pegues, Ph.D.,

Scientific Review Administrator, Special

Review, Referral, and Resources Branch,

Division of Extramural Activities, National

Cancer Institute, 6116 Executive Boulevard,

Room 8084, Bethesda, MD 20892, 301/594–

1286.

This notice is being published less than 15

days prior to the meeting due to scheduling

conflicts. Any interested person may file

written comments with the committee by

forwarding the statement to the Contact

Person listed on this notice. The statement

should include the name, address, telephone

number and when applicable, the business or

professional affiliation of the interested

person.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: April 17, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–10204 Filed 4–24–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Meeting

Pursuant to section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

Sickle Cell Disease Advisory

Committee.

The meeting will be open to the

public, with attendance limited to space

available. Individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

Name of Committee: Sickle Cell Disease

Advisory Committee.

Date: June 4, 2001.

Time: 8 a.m. to 5 p.m.

Agenda: Discussion of program policies

and issues.

Place: National Institutes of Health, Two

Rockledge Center, Conference Room 9112,

9116, 6701 Rockledge Drive, Bethesda, MD

20892.

Contact Person: Charles M. Peterson, MD,

Director, Blood Diseases Program, Division of

Blood Diseases and Resources, National

Heart, Lung, and Blood Institute, NIH, Two

Rockledge Center, Room 10158, MSC 7950,

6701 Rockledge Drive, Bethesda, MD 20892,

301/435–0050.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and

Vascular Diseases Research 93.838, Lung

Diseases Research; 93.839, Blood Diseases

and Resources Research, National Institutes

of Health, HHS)

Dated: April 18, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–10198 Filed 4–24–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse

and Alcoholism; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute on

Alcohol Abuse and Alcoholism Special

Emphasis Panel.

Date: April 24, 2001.

Time: 7:30 a.m. to 9:30 am.

Agenda: To review and evaluate grant

applications.

Place: 6000 Executive Blvd., Rm. 409,

Rockville, MD 20892, (Telephone Conference

Call).

Contact Person: Sean O’Rourke, Scientific

Review Administrator, Extramural Project

Review Branch, National Institute on Alcohol